Dr. Meisel on Emerging Treatment Strategies in TNBC

Partner | Cancer Centers | <b>Winship</b>

Jane L. Meisel, MD, an assistant professor in the Department of Gynecology & Obstetrics at Emory School of Medicine, Winship Cancer Institute, discusses emerging treatment strategies in triple-negative breast cancer (TNBC).

Jane L. Meisel, MD, an assistant professor in the Department of Gynecology & Obstetrics at Emory School of Medicine, Winship Cancer Institute, discusses emerging treatment strategies in triple-negative breast cancer (TNBC).

Of the potential combination strategies to emerge, one of the most exciting has been the combination of PARP inhibitors and immunotherapy agents, says Meisel. Preliminary phase I data have already shown the benefit of PARP inhibitors in the platinum-resistant ovarian cancer population. Though these are two different malignancies, there are similarities between patient populations, especially those with BRCA mutations, says Meisel.

Another area of interest is the androgen receptor (AR)-positive patients, in which there are some interesting data with enzalutamide (Xtandi), states Meisel. Though there are no established biomarkers of response, investigators will continue to identify potential targets for treatment, concludes Meisel.